Pillars of growth
Heavy bet for R&D
as a future
growth engine

Heavy bet on R&D
as a future
growth engine


Biosimilars
A great growth opportunity for ROVI in a market that totals more than 1,000 million euros in Europe.

Pharmaceutical products
Diversified portfolio of innovative own and licensed products protected by patents.

Low Molecular Weight Heparin
ROVI's principal product, a low-molecular-weight heparin developed in-house.

Contract manufacturing
High production capacity with four manufacturing plants for prefilled syringes and oral solid forms.

Rovi in figures

+119%
Net profit of the businessin 2019

+46%
2019 LMWHglobal sales

65 countries
LMWH presence through strategic alliances with international partners

6 plants
for manufacturing own and third-party products in Spain

€29,3 Mn
of investment in R&D in 2019 Commitment to innovation

7 countries
Direct presence through subsidiaries to market Enoxaparin
Information for investors
Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.
Last news on Rovi
13/01/2021
ROVI completes the manufacture of the first batches of Moderna vaccine
Laboratorios Farmacéuticos Rovi, S.A. (BME -Spanish Stock Exchanges and Markets: ROVI), a pan-European specialised company engaged in the research, development and marketing of biological specialties and a manufacturer with a high degree of technological
27/11/2020
The Journal npj Schizophrenia Publishes the Results of the PRISMA-3 Study of the Efficacy and Safety of Doria® in Schizophrenic Patients
The results of the phase III pivotal clinical trial show that the once-monthly injectable antipsychotic Doria® furnishes a significant improvement in the symptomatology and severity of the illness in patients with acute exacerbation of schizophrenia.
Last annual report

Annual Report 2019
Last regular
public information
